2004 FDA Pharmaceutical Companies 
STAT
DECEMBER 7, 2023
But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work. Not long after the patent was awarded, the company leveraged federally funded research and began investigating different forms of the compound, called Revlimid.
The FDA Law Blog
MARCH 18, 2025
Koblitz Integral to the careful balance Congress struck when passing the Hatch-Waxman Amendments, the patent term extension (PTE) is intended to restore patent life that was consumed during regulatory review of an FDA-regulated product. FDA has already been there , of course, with respect to 180-day exclusivity.)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JULY 4, 2024
In the US, botanical dietary supplements can be sold without US Food and Drug Administration (FDA) approval, 1 prompting many vendors to promote the use of botanical products as dietary supplements , 2 rather than pursue a path of regulatory approval. 3 Is two too few? 3 Is two too few?
pharmaphorum
DECEMBER 28, 2022
So, how do smaller pharmaceutical companies at the cutting edge get ready for their acquisition milestone, so they maximise their value and attractiveness? Any purchasing company would ideally like to integrate their acquisitions into their company seamlessly. She joined NSF in 2017.
pharmaphorum
NOVEMBER 22, 2021
Clinical research in VR as a treatment for PTSD was accelerated in 2004 when an epidemiological study of PTSD was published , noting the rise in cases among veterans of the conflicts in Iraq and Afghanistan. Skip says this paper was a “call to arms” to find improved treatment methods.
European Pharmaceutical Review
MARCH 7, 2024
Lastly, there is growing prominence and interest in radioligand therapeutics within major pharmaceutical companies, who are increasingly investing in this field, evident through recent acquisitions of Point Biopharma and RayzeBio. What makes targeted alpha therapies a promising new approach against cancer?
Pharmaceutical Technology
OCTOBER 5, 2022
In 2009, Tysabri was performing well, having yielded $776 million in sales after being first approved in 2004, as per Biogen’s 2009 financial filings. Ferry describes a popular solution among pharmaceutical companies. 4 integrins, which play a key role in MS pathology.
Expert insights. Personalized for you.
128 
Let's personalize your content